Caiwen Du
Shenzhen, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Pyrotinib Plus Trastuzumab and Docetaxel with Different Antidiarrheal Strategies in Patients with HER2-Positive Recurrent or Metastatic Breast Cancer (PHAENNA): A Multicenter, Phase 1 Trial.
Journal: Cancer research and treatment
Published: April 12, 2026
Dalpiciclib combined with endocrine therapy for patients with HR+/HER2- metastatic breast cancer: a multicenter real-world study.
Journal: Therapeutic advances in medical oncology
Published: January 16, 2026
Utidelone exhibits favorable responses in refractory patients with advanced breast cancer.
Journal: Translational cancer research
Published: December 26, 2025
Inetetamab-Based Regimens for Patients with HER2-Positive Metastatic Breast Cancer: A Real-World Retrospective Study.
Journal: Breast cancer (Dove Medical Press)
Published: August 08, 2025
Delayed Cardiac Dysfunction During Prolonged Use of Trastuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer.
Journal: Breast cancer (Dove Medical Press)
Published: July 25, 2025
Efficacy and safety of eribulin plus gemcitabine as second-line treatment for recurrent HER2-negative breast cancer: a phase II, single-arm, open-label trial.
Journal: Communications medicine
Published: February 19, 2025
Final Efficacy and Safety Results of Pyrotinib Combined With Trastuzumab and Chemotherapy in Pre-Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Journal: Cancer medicine
Published: January 19, 2025
Clinicopathological Features and Prognoses of Patients With Splenic Metastases From Breast Cancer: A Single-Centre, Retrospective Study.
Journal: Cancer control : journal of the Moffitt Cancer Center
Published: January 04, 2025
Low-dose apatinib in combination with chemotherapy for hormone receptor-positive, HER2-negative breast cancer with pulmonary lymphangitic carcinomatosis: A case report.
Journal: Medicine
Published: November 13, 2024
Apatinib and trastuzumab-based chemotherapy for heavily treated primary trastuzumab-resistant metastatic breast cancer.
Journal: Journal of cancer research and therapeutics
Published: May 20, 2024
Utidelone combined with anti‑angiogenic therapy for the treatment of anthracycline/taxane‑treated and endocrine‑resistant HR+/HER2‑ refractory breast cancer with brain metastases: A case report.
Journal: Oncology letters
Published: April 25, 2024
Last Updated: 09/26/2026